Blood Pressure is Never Truly Static
Blood pressure variability refers to the fluctuations in blood pressure continuously over our lifespan. While these fluctuations happen naturally, higher variability poses independent risk factors for stroke, heart attack and organ damage even when average BP is controlled [x].
In clinical trials, variability introduces direct consequences for statistical power, data integrity, regulatory submission, and ultimately, the validity of a trial’s conclusions.
As May Measure Month and World Hypertension Day (17th May) bring focus to blood pressure measurement standards globally, we take a moment to examine the specific sources of variability that clinical teams encounter in trial settings, and what they mean in practice
6 Principal Sources of Variability
1. Biological Variability
Blood pressure is inherently dynamic. Fluctuations occur throughout the day in response to physical activity, emotions, posture, sleep quality, meals, temperature and circadian rhythms. This biological variability is well documented, but in clinical trials, successful outcomes depend on whether these changes are accounted for.
Measuring blood pressure at different times of day, under inconsistent conditions pre-measurement, and without rest periods will reflect more biological noise than treatment efficacy. Protocols which do not include controlled measurement windows, and permit site-level flexibility, introduce variability with significant consequences downstream.
2. The White Coat Effect
The White Coat Effect (WCE) is a well-documented phenomenon in which blood pressure recorded in clinical settings is systematically higher than readings taken outside them. The 2018 ESC Guidelines estimate WCE may account for up to 30-40% of office-based elevated BP readings, making it one of the most significant causes of bias in blood pressure measured in clinical trials.
In trials where office blood pressure serves as the primary endpoint, the white coat effect can compress apparent treatment differences, reduce sensitivity to change, and cause eligibility misclassification. It may also create artefactual apparent responders or non-responders depending on how it evolves across visits.
Ambulatory blood pressure monitoring (ABPM) mitigates this effect by capturing readings across normal daily conditions. ABPM is referred to as the gold standard for the management and diagnosis of hypertension.
3. Device and Cuff-Related Sources
Not all blood pressure devices are equal, and device selection is a foundational data quality decision. Differences in oscillometric algorithms, validation status, and population-specific performance mean that device choice directly affects the comparability of readings across both sites and studies.
Equally, cuff sizing errors are a persistent and underappreciated source of variability. An inappropriately small cuff on a large arm may overestimate systolic pressure; an oversized cuff may underestimate it. In some cases, magnitude of error can exceed 10 mmHg, which is enough to misclassify patients, and distort endpoints.
Older devices may see a calibration drift over a multi-year study, and inconsistent maintenance practices across sites, add further layers of technical variability that are difficult to detect without proactive monitoring.
4. Operator and Procedural Variability
In multi-site trials, differences in how site staff conduct blood pressure measurements are a major source of variability. These include:
- Patient positioning
- Rest period prior to measurement
- Number of measurements
- Averaging rules
- Handling of talking or movement during measurement
Training at site initiation is necessary but often not sufficient. Protocol deviation patterns in BP measurement tend to emerge gradually and vary by site, making ongoing monitoring and targeted retraining an operational requirement rather than an exception.
5. Timing Windows and Protocol Adherence
Blood pressure measurements are time sensitive. Readings taken outside protocol-defined windows introduce systematic errors that can misrepresent pharmacodynamic profiles or obscure true trough effects.
In practice, timing window deviations are common, particularly in decentralised or hybrid trial designs where measurement responsibility shifts to the patient or home health professionals. Without robust data capture systems that flag deviations in real time, deviations accumulate silently and become a significant source of variability.
6. Decentralised and Home Measurement Contexts
The increasing adoption of decentralised trial designs has expanded the use of home blood pressure monitoring (HBPM). This brings genuine advantages to the study, but also introduces new variability challenges.
Patient technique varies substantially without direct supervision. Device standardisation across a large, geographically distributed patient population is logistically demanding. Data transmission gaps, time-stamping inconsistencies, and informal measurement conditions (non-fasting, post-exercise, incorrect posture) all affect data quality in ways that are harder to detect and adjudicate than equivalent issues in a clinical setting.
Practical Considerations for Sponsors and CROs
Reducing measurement variability begins at the design stage and requires sustained attention through to database lock. Key considerations include:
Based on validated performance in the relevant population, not convenience or site familiarity. Particularly important for paediatric, elderly, or high-comorbidity populations where standard validation may not apply.
Must be detailed enough to be operationally actionable — specifying rest duration, posture, cuff size selection criteria, number of readings, and explicit averaging rules.
Should include practical demonstration and competency certification, not instruction alone.
Real-time review of blood pressure data patterns, flagging implausible value clustering, consistent rounding, or timing deviations that may indicate procedural non-compliance.
Should be addressed explicitly in study design, even where office BP is the primary endpoint, given its value in interpreting apparent non-response and managing white coat confounding.
Conclusion
Blood pressure may appear to be a straightforward measurement, but the gap between a well-designed measurement protocol and reliable endpoint data is substantial. Measurement variability is not an unavoidable feature of cardiovascular trials; it can be managed, provided it is taken seriously at every stage of study design and execution.
At dabl, this is where our expertise lies: ensuring that blood pressure data captured in clinical trials reliable, defensible under regulatory scrutiny, and reflective of true treatment effect. Contact us to learn more.
